We have previously reported that both paclitaxel and cisplatin, standard chemotherapies used for the treatment of ovarian cancer patients, promotes an increase in the expression of the chemoresistant markers ERCC1 and TUBB3 and the CSC markers CD44, CD133, OCT4A and EpCAM in ovarian cancer cells, [16, 18, 19, 60]. Here, PROM1 is linked to ovarian carcinoma.